Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Roswell Park Cancer Institute
Genmab
AstraZeneca
National Institutes of Health Clinical Center (CC)
Genmab
AvenCell Therapeutics, Inc.
Medical University of South Carolina
City of Hope Medical Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Chinese PLA General Hospital
National Institutes of Health Clinical Center (CC)
University of Chicago
Allogene Therapeutics
National Institutes of Health Clinical Center (CC)
Ossium Health, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Essen Biotech
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
University of Michigan Rogel Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
ARCE Therapeutics, Inc.
St. Jude Children's Research Hospital
UNC Lineberger Comprehensive Cancer Center
Fred Hutchinson Cancer Center
National Institutes of Health Clinical Center (CC)
St. Jude Children's Research Hospital
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
M.D. Anderson Cancer Center
Chinese PLA General Hospital
Indapta Therapeutics, INC.
M.D. Anderson Cancer Center
Thomas Jefferson University
Instituto Nacional de Cancer, Brazil
Affiliated Hospital to Academy of Military Medical Sciences
Hoffmann-La Roche
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Celgene
University Hospital Heidelberg
Columbia University